Amy E.  Herr net worth and biography

Amy Herr Biography and Net Worth

Director of Bio-Techne

Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining the faculty at UC Berkeley in 2007, Dr. Herr has served in several university, national, and international leadership roles including as the Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub – an incubator for academic spin-out companies, and on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB) for the National Institutes of Health, as well as governmental science advisory boards. Dr. Herr was a co-founder and advisory board member of Zephyrus Biosciences, which was acquired by Bio-Techne in 2016. Dr. Herr holds a Doctor of Philosophy in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering & Applied Science from Caltech.

What is Amy E. Herr's net worth?

The estimated net worth of Amy E. Herr is at least $120,674.32 as of February 14th, 2025. Dr. Herr owns 1,976 shares of Bio-Techne stock worth more than $120,674 as of March 25th. This net worth evaluation does not reflect any other assets that Dr. Herr may own. Learn More about Amy E. Herr's net worth.

How do I contact Amy E. Herr?

The corporate mailing address for Dr. Herr and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at ir@bio-techne.com. Learn More on Amy E. Herr's contact information.

Has Amy E. Herr been buying or selling shares of Bio-Techne?

During the last quarter, Amy E. Herr has sold $122,685.60 in Bio-Techne stock. Most recently, Amy E. Herr sold 1,860 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a transaction totalling $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares of the company's stock, valued at $130,336.96. Learn More on Amy E. Herr's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), Amy Herr (Director), John Higgins (Director), James Hippel (CFO), Kim Kelderman (CEO, President & Director), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 15,252 shares worth more than $1,157,753.28. The most recent insider tranaction occured on February, 14th when Director Amy E Herr sold 1,860 shares worth more than $122,685.60. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 2/14/2025.

Amy E. Herr Insider Trading History at Bio-Techne

See Full Table

Amy E. Herr Buying and Selling Activity at Bio-Techne

This chart shows Amy E Herr's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$123ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $60.36
Low: $60.27
High: $61.86

50 Day Range

MA: $67.84
Low: $58.47
High: $78.75

2 Week Range

Now: $60.36
Low: $56.60
High: $85.57

Volume

492,700 shs

Average Volume

1,077,827 shs

Market Capitalization

$9.54 billion

P/E Ratio

61.02

Dividend Yield

0.53%

Beta

1.3